-
Product Insights
Cognitive Impairment - Drugs In Development, 2024
Empower your strategies with our Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Cognitive impairment is a condition characterized by a decline in cognitive functions, such as memory, attention, and problem-solving skills. It can range from mild to severe and may result from various causes, including aging, neurodegenerative diseases (like Alzheimer's), vascular disorders, traumatic brain injuries, infections, medication side effects, mental health issues, nutritional deficiencies, or environmental factors. Symptoms can include memory loss, confusion, difficulty...
-
Product Insights
Frontotemporal Dementia (FTD) - Drugs In Development, 2024
Empower your strategies with our Frontotemporal Dementia (FTD) – Drugs In Development, 2024 report and make more profitable business decisions. Frontotemporal dementia (FTD) encompasses various brain disorders leading to progressive damage in the frontal and temporal lobes. It manifests in distinct ways: behavioral changes, language difficulties, or movement impairments. Symptoms range from altered social conduct, lack of empathy, and impulsivity to language struggles or motor coordination issues. FTD's exact cause remains unclear, but abnormal protein deposits in the brain are implicated....
-
Product Insights
Dyskinesia - Drugs In Development, 2024
Empower your strategies with our Dyskinesia – Drugs In Development, 2024 report and make more profitable business decisions. Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. The disease can be controlled by healthy life style and medication. The Dyskinesia drugs in development market research report provide comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by...
-
Product Insights
Seizures - Drugs In Development, 2024
Empower your strategies with our Seizures – Drugs In Development, 2024 report and make more profitable business decisions. A seizure is a medical condition where the patient has a temporary, unstoppable surge of electrical brain activity. Affected brain cells uncontrollably fire signals to others around them, overloading the affected areas of the brain. That overload can cause a wide range of symptoms or effects, including abnormal sensations, passing out, and uncontrolled muscle movements. Up to 11% of people in the US...
-
Product Insights
Childhood Epilepsy - Drugs In Development, 2024
Empower your strategies with our Childhood Epilepsy – Drugs In Development, 2024 report and make more profitable business decisions. Childhood epilepsy is a neurological disorder characterized by recurring seizures in children. Seizures result from abnormal electrical activity in the brain, causing temporary disruptions in behavior, awareness, sensation, or consciousness. This condition can manifest in various forms, from brief staring spells to convulsions or loss of consciousness. The causes of childhood epilepsy can vary, including genetic factors, brain injury, infections, developmental disorders,...
-
Product Insights
Neuropathy - Drugs In Development, 2024
Empower your strategies with our Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Neuropathy, also known as peripheral neuropathy, refers to a condition involving damage or dysfunction of the nerves outside the brain and spinal cord (peripheral nerves). This condition can affect a single nerve or multiple nerves and can result from various causes. Common types include diabetic neuropathy, resulting from diabetes-related nerve damage due to high blood sugar levels; peripheral neuropathy, often due to conditions...
-
Product Insights
Relapsing Remitting Multiple Sclerosis (RRMS) - Drugs In Development, 2024
Empower your strategies with our Relapsing Remitting Multiple Sclerosis (RRMS) – Drugs In Development, 2024 report and make more profitable business decisions. Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS), a chronic autoimmune condition that affects the central nervous system. In RRMS, individuals experience intermittent episodes of new or worsening symptoms (relapses or exacerbations) lasting days to weeks, followed by periods of partial or complete recovery (remission) with stable or improved function. Symptoms of RRMS can...
-
Product Insights
Dementia Associated With Alzheimer's Disease - Drugs In Development, 2024
Empower your strategies with our Dementia Associated With Alzheimer's Disease – Drugs In Development, 2024 report and make more profitable business decisions. Alzheimer's disease (AD) is the most common cause of dementia. AD is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and changes in behavior and thinking skills that interfere with daily functioning. Early symptoms may include mild forgetfulness, difficulty recalling recent events or information, and trouble with problem-solving or complex tasks. One of the hallmark features of...
-
Product Insights
Lewy Body Dementia - Drugs In Development, 2024
Empower your strategies with our Lewy Body Dementia – Drugs In Development, 2024 report and make more profitable business decisions. Lewy body dementia (LBD) is a progressive neurodegenerative disorder characterized by the abnormal accumulation of alpha-synuclein protein deposits (Lewy bodies) in the brain. This condition shares similarities with both Alzheimer's disease and Parkinson's disease, presenting a complex spectrum of symptoms that affect cognition, movement, behavior, and autonomic functions. LBD manifests through various symptoms that may fluctuate in severity, including cognitive changes...
-
Product Insights
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drugs In Development, 2024
Empower your strategies with our Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Drugs In Development, 2024 report and make more profitable business decisions. Multiple system atrophy (MSA), or Shy-Drager syndrome, is a neurological disorder that impairs the body's involuntary functions (blood pressure, heart rate, bladder function, and digestion). Symptoms include rigid muscles, bradykinesia, tremors, dysarthria, dysphagia, constipation, incontinence, and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications. The Multiple System Atrophy (MSA or Shy-Drager...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.